Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability

Patent metadata

Field	Value
Publication number	US-9763887-B2
Application number	US-201414210850-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm.

First claim

What is claimed is:

1. A mesalamine pharmaceutical composition for delivery of mesalamine to the colon with reduced delivery variability, the composition consisting essentially of a capsule containing (i) at least one first dosage element comprising a first mesalamine dose and a first enteric coating and (ii) at least one second dosage element comprising a second mesalamine dose and a second enteric coating, wherein the first enteric coating is soluble at a pH of about 6.4 to about 6.8 in an aqueous phosphate buffer and the second enteric coating is soluble in an aqueous phosphate buffer at a pH of 0.2 to 1 units higher than the first enteric coating, wherein the solubility of the first and second enteric coating in aqueous phosphate buffer is determined after an initial exposure of the composition in 0.1 N hydrochloric acid for 2 hours at a paddle speed of 100 followed by 1 hour in a 6.0 pH phosphate buffer at a paddle speed of 100 rpm and the first enteric coating of the first dosage element and second enteric coating of the second dosage element are soluble at the pH in aqueous phosphate buffer such that after 60 minutes at least 70% of the mesalamine has been released from said dosage element using a paddle apparatus 2 with a paddle speed of 100 rpm and wherein the combined number of first dosage element contains about 50% by weight of the total mesalamine in the composition and the at least one second dosage element contains about 50% by weight of the total mesalamine in the composition.

2. The mesalamine pharmaceutical composition of claim 1 ,
wherein the at least one first dosage element releases mesalamine in an amount of at least about 30% to about 50% by weight of the total mesalamine in the composition over 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm, and the at least one second dosage element releases mesalamine in an amount of at least about 40% to about 50% by weight of the total mesalamine in the composition over 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm.

3. The mesalamine pharmaceutical composition of claim 2 , wherein the first dosage element releases about 40% to about 50% by weight of the composition over 60 minutes at a pH of about 6.6.

4. The mesalamine pharmaceutical composition of claim 1 , wherein the pH at which the second enteric coating is soluble is 0.4 to 0.8 higher than the pH at which the first enteric coat is soluble.

5. The mesalamine pharmaceutical composition of claim 1 , wherein the pH at which the second enteric coating is soluble is 0.5 to 0.6 higher than the pH at which the first enteric coat is soluble.

6. The mesalamine pharmaceutical composition of claim 2 , wherein the capsule contains two first dosage elements and two second dosage elements.

7. The mesalamine pharmaceutical composition of claim 6 ,
wherein the enteric coating of the first dosage element is different from the enteric coating of the second dosage element.

8. The mesalamine pharmaceutical composition of claim 7 ,
wherein the first enteric coating is a mixture of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1 and
the second enteric coating is selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1.

9. The mesalamine pharmaceutical composition of claim 8 , wherein the mixing weight ratio of the first enteric coating is 9:1 to 1:9.

10. The mesalamine pharmaceutical composition of claim 9 , wherein the mixing weight ratio of the first enteric coating is 6:4 to 4:6.

11. The mesalamine pharmaceutical composition of claim 10 , wherein the mixing weight ratio of the first enteric coating is about 5:5.

Assignees

• Warner Chilcott Co Llc
• Allergan Pharmaceuticals Int Ltd

Inventors

• Loughlin Ryan Gerald
• Mccullagh Stephen
• Boissonneault Roger

Classifications

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61K9/2846 Primary

  Poly(meth)acrylates · CPC title

• A61K9/2886

  having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209) · CPC title

• A61K31/606

  having amino groups · CPC title

• A61K9/4808

  characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084) · CPC title